Short answer
PTC THERAPEUTICS, INC. (PTCT) filed an 8-K current report with the SEC on September 21, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). PTC completed acquisition of ST-920 from Sangamo, a BLA-stage one-time AAV gene therapy candidate for Fabry disease.
PTC THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- PTC completed acquisition of ST-920 from Sangamo, a BLA-stage one-time AAV gene therapy candidate for Fabry disease
- Asset-stage acquisition adds a potentially near-commercial rare-disease therapy to PTC’s pipeline
- Press release furnished as Exhibit 99.1 contains transaction details and strategic implications
Item 8.01 · Other Events
- Acquisition completed September 21, 2026, expanding PTC Therapeutics’ development portfolio
- Rolling U.S. BLA submission for ST-920 expected in fourth quarter 2026
- Accelerated approval application supported by 52-week Phase 1/2 STAAR renal-function and safety data
- Planned regulatory filings outside the United States broaden ST-920’s commercial opportunity
Item EX-99.1 · Exhibit EX-99.1
- Acquisition of ST-920 from Sangamo completed, adding a BLA-stage Fabry disease gene therapy to PTC’s rare-disease portfolio
- Rolling FDA BLA submission targeting completion in Q4 2026, with accelerated approval potential
- One-time AAV therapy could reduce dependence on chronic enzyme replacement therapy if durability and safety translate commercially
- FDA designations include Orphan Drug, Fast Track and RMAT, supporting regulatory engagement but not approval
- Key risks: BLA completion, regulatory approval, reimbursement, commercialization and potential ST-920 milestone payments
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PTC THERAPEUTICS, INC. 8-K filings
Get the next PTCT 8-K as it lands
Follow PTCT for push alerts, or ask the research agent what this filing means.